Tools   Select Another Resource Report Type

https://labnodes.vanderbilt.edu/community/profile/id/2230

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 30,2023. Core facility that supports diabetes, endocrine, and metabolic research across a range of species. Its objective is to provide sensitive, reproducible, and inexpensive analyses of hormones, amino acids, and other relevant chemicals.

Proper citation: Vanderbilt Diabetes Research and Training Center Hormone Assay and Analytical Services Core Facility (RRID:SCR_010181) Copy   

•   Source: SciCrunch Registry

http://www.isletstudy.org/

Network of centers to conduct studies of islet transplantation in patients with type 1 diabetes to improve the safety and long-term success of methods for transplanting islets. It is the aim of this trial to improve methods of isolating islets, to improve techniques for the administering those transplanted islets; and to develop approaches to minimize the toxic effects of immunosuppressive drugs required for transplantation.

Proper citation: Clinical Islet Transplantation Study (RRID:SCR_001515) Copy   

•   Source: SciCrunch Registry

http://www.t1diabetes.nih.gov/T1D-PTP/

THIS RESOURCE IS NO LONGER IN SERVICE, documented August 22, 2016. Investigator access is provided to the established facilities and expertise needed to extend, enhance and validate preclinical studies of promising new therapeutics in cases where additional preclinical testing is needed to validate potential therapies under disease-specific conditions and in multiple animal models before therapeutics can enter the Type 1 Diabetes Rapid Access to Intervention Development (T1D-RAID) development pipeline. The T1D-RAID program provides resources for pre-clinical development of drugs, natural products, and biologics that will be tested as new therapeutics in type 1 diabetes clinical trials. The T1D-RAID program is not currently accepting applications. The T1D-PTP program currently supports two contracts, which are separate from each other and from the T1D-RAID NCI contract resources, to assist in preclinical development of therapeutics for T1D: * Agents to be tested for Preclinical Efficacy in Prevention or Reversal of Type 1 Diabetes in Rodent Models. Type 1 Diabetes Preclinical Testing Program (T1D-PTP) (NOT-DK-09-006) * Needs for Preclinical Efficacy Testing of Promising Agents to Prevent or Reverse Diabetic Complications (NOT-DK-09-009) The T1D-RAID and T1D-PTP are programs intended to remove the most common barriers to progress in identification and development of new therapies for Type 1 Diabetes. The common goal of these programs is to support and provide for the preclinical work necessary to obtain proof of principle establishing that a new molecule or novel approach will be a viable candidate for expanded clinical evaluation.

Proper citation: Type 1 Diabetes Preclinical Testing Program (RRID:SCR_006861) Copy   

•   Source: SciCrunch Registry

http://diabetes.niddk.nih.gov/dm/pubs/control/index.aspx

Clinical study that showed that keeping blood glucose levels as close to normal as possible slows the onset and progression of eye, kidney, and nerve diseases caused by diabetes. EDIC is a follow-up study of people who participated in DCCT. The DCCT involved 1,441 volunteers, ages 13 to 39, with type 1 diabetes and 29 medical centers in the United States and Canada. Volunteers had to have had diabetes for at least 1 year but no longer than 15 years. They also were required to have no, or only early signs of, diabetic eye disease. The study compared the effects of standard control of blood glucose versus intensive control on the complications of diabetes. Intensive control meant keeping hemoglobin A1C levels as close as possible to the normal value of 6 percent or less. The A1C blood test reflects a person''''s average blood glucose over the last 2 to 3 months. Volunteers were randomly assigned to each treatment group. DCCT Study Findings * Intensive blood glucose control reduces risk of ** eye disease: 76% reduced risk ** kidney disease: 50% reduced risk ** nerve disease: 60% reduced risk When the DCCT ended, researchers continued to study more than 90 percent of participants. The follow-up study, called Epidemiology of Diabetes Interventions and Complications (EDIC), is assessing the incidence and predictors of cardiovascular disease events such as heart attack, stroke, or needed heart surgery, as well as diabetic complications related to the eye, kidney, and nerves. The EDIC study is also examining the impact of intensive control versus standard control on quality of life. Another objective is to look at the cost-effectiveness of intensive control. EDIC Study Findings * Intensive blood glucose control reduces risk of ** any cardiovascular disease event: 42% reduced risk ** nonfatal heart attack, stroke, or death from cardiovascular causes: 57% reduced risk

Proper citation: Diabetes Control and Complications Trial (RRID:SCR_006805) Copy   

•   Source: SciCrunch Registry

https://www.accordtrial.org/public

Study testing whether strict glucose control lowers the risk of heart disease and stroke in adults with type 2 diabetes. In addition the study is exploring: 1) Whether in the context of good glycemic control the use of different lowering lipid drugs will further improve these outcomes and 2) If strict control of blood pressure will also have additional beneficial effects on reducing cardiovascular disease. The design was a randomized, multicenter, double 2 X 2 factorial trial in 10,251 patients with type 2 diabetes mellitus. It was designed to test the effects on major CVD events of intensive glycemia control, of fibrate treatment to increase HDL-cholesterol and lower triglycerides (in the context of good LDL-C and glycemia control), and of intensive blood pressure control (in the context of good glycemia control), each compared to an appropriate control. All 10,251 participants were in an overarching glycemia trial. In addition, one 2 X 2 trial addressed the lipid question in 5,518 of the participants and the other 2 X 2 trial addressed the blood pressure question in 4,733 of the participants. The glycemia trial was terminated early due to higher mortality in the intensive compared with the standard glycemia treatment strategies. The results were published in June 2008 (N Eng J Med 2008;358:2545-59). Study-delivered treatment for all ACCORD participants was stopped on June 30, 2009, and the participants were assisted as needed in transferring their care to a personal physician. The lipid and blood pressure results (as well as the microvascular outcomes and eye substudy results) were published in 2010. All participants are continuing to be followed in a non-treatment observational study.

Proper citation: ACCORD (RRID:SCR_009015) Copy   

•   Source: SciCrunch Registry

https://www.baderc.org/cores/metaboliccore/

Core in BADERC that provides services in consultation and teaching, use of DEXA scanner for determination of body fat and/or bone density, and use of Coulter Counter to measure cell number and cell size distribution.

Proper citation: Boston Area Diabetes Endocrinology Research Center Metabolic Physiology and Energy Balance Core Facility (RRID:SCR_008293) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012e-6d67-5282-55da-381e80000000

Core facility that provides the following services: Autoantibody determination, HLA typing and Genotyping for the best recognized susceptibility loci (INS, PTPN22, CTLA4).

The Human Sample Procurement Core will support translational research endeavors within the JDRF Center by providing the Center''s laboratories access to well-characterized blood samples from patients with diabetes at different stages of the disease. This availability will greatly facilitate the translational exploration of concepts and targets emerging from the basic research projects. Individuals with T1D (recent onset, long-standing Type-1 diabetes) and matched controls (healthy or T2D) will be recruited from the patient population at the Joslin Diabetes Center and neighboring institutions. The Core will perform and record a basic characterization of patients and their samples. This analysis will include a thorough evaluation of clinical characteristics from a diabetes and autoimmune standpoint, and an immunogenetic workup (outsourced to Joslin or other cores): autoantibody determination, HLA typing and genotyping for the best recognized susceptibility loci (INS, PTPN22, CTLA4). A relational database will be adapted to record all patient information, copies of which will be provided in a de-identified manner to the investigators.

Proper citation: HMS Human Sample Procurement Core Facility (RRID:SCR_009797) Copy   

•   Source: SciCrunch Registry

http://harvard.eagle-i.net/i/0000012a-25bf-69ed-f5ed-943080000000

Core facility that provides the following services: Maintainence and dissemination of transgenic and mutant mice.

The Genetically Modified NOD Mouse Core provides Center investigators, as well as researchers elsewhere, with access to transgenic and mutant lines derived from the NOD mouse model: some will be generated within the Core; others are established lines of proven experimental value that are maintained in the Core. The Core will construct transgenic mice in strains that have a high susceptibility to diabetes (in particular in the NOD line). This includes trangenesis by conventional pronuclear injection or by delivery of RNAi cassettes on lentiviral vectors. The Core will also provide a panel of existing transgenic and mutant lines. These lines are chosen because of their established interest in allowing the dissection of immunological tolerance in Type 1 Diabetes, and in response to Center investigator needs.

Proper citation: HMS Genetically Modified NOD Mouse Core Facility (RRID:SCR_009796) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Flow-Cytometry-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides cell sorting and flow cytometry services. Specific services include cell analysis, large object sorting,magnetic cell enrichment, and automatic cell counting.

Proper citation: Joslin Diabetes Center Flow Cytometry Core Facility (RRID:SCR_009878) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Animal-Physiology-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides technically advanced physiological evaluation of metabolism in diabetes, obesity, and their associated complications in rodents for DRC investigators and outside users. It also provides training of investigators and trainees in several physiological procedures.

Proper citation: Joslin Diabetes Center Animal Physiology Core Facility (RRID:SCR_009876) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Advanced-Microscopy-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for performing specific morphological procedures, providing training and access to equipment, maintaining the specialized microscopes, and giving advice and interpretation.

Proper citation: Joslin Diabetes Center Advanced Microscopy Core Facility (RRID:SCR_009875) Copy   

•   Source: SciCrunch Registry

https://joslinresearch.org/drc-cores/Advanced-Genomics-and-Genetics-Core

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on October 27,2023. Core that provides services for genetic and genomic analysis, including DNA extraction from blood, access to DNA collections from the Core?s repository, SNP genotyping, and support for gene expression studies based on both high-density oligonucleotide arrays and real-time quantitative PCR.

Proper citation: Joslin Diabetes Center Advanced Genomics and Genetics Core Facility (RRID:SCR_009873) Copy   

•   Source: SciCrunch Registry

http://jsu.eagle-i.net/i/0000012c-1c64-7caa-a830-7bcf80000000

The JHS is the largest single-site longitudinal, population-based, cohort study of 5,302 persons initiated in the fall of 2000 to prospectively investigate the determinants of CVD among African Americans in the Jackson, MS metropolitan statistical area. The JHS investigates the various genotype and phenotype factors that affect high blood pressure, heart disease, strokes, diabetes and other important diseases in African Americans. The primary objective of the Jackson Heart Study is to investigate the causes of cardiovascular disease (CVD) in African Americans to learn how to best prevent this group of diseases in the future. More specific objectives include: 1. Identification of factors, which influence the development, and worsening of CVD in African Americans, with an emphasis on manifestations related to high blood pressure (such as remodeling of the left ventricle of the heart, coronary artery disease, heart failure, stroke and disorders affecting the blood vessels of the kidney). 2. Building research capabilities in minority institutions at the undergraduate and graduate level by developing partnerships between minority and majority institutions and enhancing participation of minority investigators in large-scale epidemiologic studies. 3. Attracting minority students to and preparing them for careers in health sciences.

Proper citation: Jackson Heart Study (RRID:SCR_009902) Copy   

•   Source: SciCrunch Registry

https://einsteinmed.edu/centers/diabetes-research/research-areas/biomedical-cores/translational-research-core/index.html

Core services include consultation, technical support and training and mentoring in clinical and translational research methods that are specifically applicable to diabetes, its complications and related metabolic disorders. Personel provides expertise in first-in-human and mechanistic studies in integrative physiology, in clinical trials of diabetes and obesity, and in application of new technologies.

Proper citation: Einstein-Mount Sinai Diabetes Research Center Translational Research Core Facility (RRID:SCR_015068) Copy   

•   Source: SciCrunch Registry

https://www.baderc.org/cores/cbmcore/

Services provided include tissue preparation, embedding and sectioning for electron microscopy, use of electron microscope and photography of thin sections, immunogold staining for electron microscopy, preparation and incubation of samples (cells and tissues) for immunofluorescence microscopy, confocal microscopy and digital imaging.

Proper citation: Boston Area Diabetes Endocrinology Research Center Cell Biology and Morphology Core Facility (RRID:SCR_015069) Copy   

•   Source: SciCrunch Registry

http://www.baderc.org/cores/molbioCore.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 24,2024. Core that provides services for DNA sequencing and oligonucleotide synthesis, as well as support for projects that require research laboratory automation, such as siRNA screens and transcript abundance profiling. It also offers experimental design and advice for automation and high throughput screening of siRNA collections based on the Ambion siRNA collection.

Proper citation: Boston Area Diabetes Endocrinology Research Center Molecular Biology (RRID:SCR_015079) Copy   

•   Source: SciCrunch Registry

https://www.derc.cuimc.columbia.edu/services/flow-cytometry-and-cell-sorting-core

Core which assists investigators to quantify and phenotypically characterize cell populations that contribute to the metabolic, immunologic and developmental programs of diabetes and its complications; and to purify populations of cells of relevance to diabetes and its complications.

Proper citation: Columbia Diabetes Research Center Flow Cytometry and Cell Sorting Core Facility (RRID:SCR_015078) Copy   

•   Source: SciCrunch Registry

http://www.baderc.org/cores/IsletCore.html

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 23,2024.Core which provides islets to the local diabetes research community in the Boston area. They collaborate with researchers nationally to provide nonhuman primate (NHP) islets for research.

Proper citation: Boston Area Diabetes Endocrinology Research Center Pancreatic Islet (RRID:SCR_015073) Copy   

•   Source: SciCrunch Registry

http://cdmd.indiana.edu/research-core/the-swine-core/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on July 14,2024. Core which utilizes a breeding colony of Ossabaw swine with metabolic syndrome and long-term complications, most notably cardiovascular disease. It provides swine maintenance (glucose tolerance tests, body composition, glucose clamp studies, and imaging studies), characterization of cardiovascular disease (intravascular ultrasound, blood flow velocity, microvascular studies), and tissues (both banked and fresh) for analysis ex vivo.

Proper citation: Indiana Diabetes Research Center Swine Core (RRID:SCR_015089) Copy   

•   Source: SciCrunch Registry

https://www.derc.cuimc.columbia.edu/services/mouse-metabolic-function-and-phenotyping-core

Core that provides services that facilitate the efficient characterization of mouse models of diabetes and its complications: NMR Body Composition Analysis, Whole Body Metabolic Assessment (chamber calorimetry with motion detection), Metabolic Clamps, Gastric Infusion/Feeding and Thermogenic Phenotyping.

Proper citation: Columbia Diabetes Research Center Mouse Metabolic Function and Phenotyping Core Facility (RRID:SCR_015082) Copy   

•   Source: SciCrunch Registry